The complement component 5 (C5) inhibitor ravulizumab demonstrated non-inferiority to eculizumab following 26 weeks of treatment in complement inhibitor-naïve and complement inhibitor-experienced patients with PNH in the study of Kulasekhara and co-authors [156]. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.